[1]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis sustained virological response and all-cause mortality[J].JAMA, 2012, 308 (24) :2584-2593.
|
[2]YU JW, WANG GQ, SUN LJ, et al.Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin[J].J Gastroenterol Hepatol, 2007, 22 (6) :832-836.
|
[3]HADZIYANNIS SJ, SETTE H JR, MORGAN TR, et al.Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.
|
[4]FERENCI P, FRIED MW, SHIFFMAN ML, et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) /ribavirin[J].J Hepatol, 2005, 43 (3) :425-433.
|
[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in Chinese) 中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.
|
[6]MANNS MP, MCHUTCHISON JG, GORDON SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial[J].Lancet, 2001, 358 (9286) :958-965.
|
[7]CAMMC, PETTA S, ENEA M, et al.Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C[J].Hepatology, 2012, 56 (3) :850-860.
|
[8]GILL U, AZIZ H, GILL ML.Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan[J].Int J Infect Dis, 2013, 17 (11) :e1017-e1021.
|
[9]CHENG ML, WANG J, ZENG AP, et al.The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response[J].Chin J Intern Med, 2012, 51 (10) :751-754. (in Chinese) 程茂良, 王珏, 曾爱平, 等.慢性丙型肝炎个体化治疗及其病毒学应答效果影响因素分析研究[J].中华内科杂志, 2012, 51 (10) :751-754.
|
[10]El RAZIKY M, FATHALAH WF, El AKEL WA, et al.The effect of peginterferon alpha-2a vs.peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients:a single centre egyptian study[J].Hepat Mon, 2013, 13 (5) :e10069.
|
[11]SINGAL AG, DHARIA TD, MALET PF, et al.Long-term benefit of hepatitis C therapy in a safety net hospital system:a cross-sectional study with median 5-year follow-up[J].BMJ Open, 2013, 3 (9) :e003231.
|
[12]XU Z, ZHANG XH, ZHAO ZX, et al.Analysis for the predictors of rapid virological response in therapy of patients with chronic hepatitis C of high viral loads[J/CD].Chin J Clinicians:Electronic Edition, 2011, 5 (18) :5327-5330. (in Chinese) 许镇, 张晓红, 赵志新, 等.高病毒载量慢性丙型肝炎快速病毒学应答的预测因素分析[J/CD].中华临床医师杂志:电子版, 2011, 5 (18) :5327-5330.
|
[13]DOU XG.The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients[J].Chin J Hepatol, 2013, 21 (6) :406-407. (in Chinese) 窦晓光.影响丙型肝炎初治患者标准化治疗疗效的相关因素及对策[J].中华肝脏病杂志, 2013, 21 (6) :406-407.
|
[14]MARIA P, SOFIA M, RAFFAELE M, et al.Chronic HCV infection affects cardiac mass in normotensives[J].J Hepatol, 2014.
|